Risk of diabetes up in hodgkin's lymphoma survivors

Risk of diabetes up in hodgkin's lymphoma survivors

(HealthDay)—Para-aortic radiation correlates with increased diabetes mellitus (DM) risk for Hodgkin's lymphoma (HL) survivors, according to a study published online Aug. 25 in the Journal of Clinical Oncology.

Frederika A. van Nimwegen, from the Netherlands Cancer Institute in Amsterdam, and colleagues examined the correlation between treatment for HL and DM risk in a cohort of 2,264 five-year HL survivors. Participants were diagnosed before age 51 years and received treatment between 1965 and 1995. Medical records and general practitioners provided treatment and follow-up information.

The researchers found that 157 patients developed DM after a median follow-up of 21.5 years. After 30 years, the overall cumulative incidence of DM was 8.3 percent. The cumulative incidence of DM was 14.2 percent after para-aortic radiation with ≥36 Gy. The risk of DM was increased 2.30-fold with irradiation with ≥36 Gy to the para-aortic lymph nodes and spleen, while the risk was increased 1.82-fold with para-aortic radiation alone with ≥36 Gy. The risk of DM was not significantly increased with lower doses (10 to 35 Gy). Higher mean to the pancreatic tail correlated with significantly increased risk of DM (P < 0.001).

"Screening for DM should be considered in follow-up guidelines for HL , and treating physicians should be alert to this increased risk," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Scientists to use tiny particles to fight big diseases

27 minutes ago

Physicians will tell you: They are not winning the war on ovarian cancer. But FIU researchers are crafting a new weapon for that battle. A group of scientists have combined medicine and advanced nanotechnological engineering ...

Popular prostate cancer therapy may be harmful

4 hours ago

A widely used treatment for prostate cancer may cause more harm than good for some patients, according to Dr. Oliver Sartor, medical director of the Tulane Cancer Center.

User comments